XENIOS AG, the technology and therapy leader in lung and heart assist becomes part of Fresenius Medical Care & Co. KGaA, Germany’s largest medical device company. – www.xenios-ag.com XENIOS is driving innovation in minimally invasive lung and heart assist, and is first to offer a complete product range that runs on ...

ESICM 2016 congress October 1-5 in Milano, Italy

Xenios looks back on a very successful ESICM 2016 congress October 1-5 in Milano, Italy. Extracorporeal CO2 removal was a main topic during the scientific lectures where the outstanding potential of this therapy to prevent ventilator-induced lung damage was discussed. On the booth we presented the Novalung therapy (interventional ...

30th EACTS Annual Meeting 1-5 October 2016. CCIB, Barcelona, Spain

Xenios at EACTS 2016 Barcelona – we presented our UNIQUE XENIOS PLATFORM and our new XENIOS CAMPUS

HEILBRONN, Germany, March 29, 2016 — XENIOS announced today that the first patient has been enrolled in the “SynCor” clinical trial of its i-cor Synchronized Cardiac Assist System for treating cardiogenic shock. The SynCor trial is a prospective, non-randomized, multi-center, open-label observational study of the safety and performance of the i-cor ...

Partnership expected to revolutionize the supply of transplantable lungs, with market launch in Europe by XENIOS expected in 2017.

45th annual meeting of the DGTHG & 48th annual meeting of the DGPK, Leipzig

We want to thank all visitors for participating in our priming challenge and for visiting our lunch symposium “Pediatric lung & heart assist reaching the next level”.